Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wolfe Research Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $20

Author: Benzinga Newsdesk | May 30, 2025 11:35am
Wolfe Research analyst Mike Polark initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Outperform rating and announces Price Target of $20.

Posted In: BBNX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist